These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30612317)

  • 1. Cancer therapeutics based on BCL-2 functional conversion.
    Pearce MC; Satterthwait AC; Zhang XK; Kolluri SK
    Apoptosis; 2019 Feb; 24(1-2):1-2. PubMed ID: 30612317
    [No Abstract]   [Full Text] [Related]  

  • 2. Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.
    Vázquez-Franco JE; Reyes-Maldonado E; Vela-Ojeda J; Domínguez-López ML; Lezama RA
    Leuk Res; 2012 Jul; 36(7):862-7. PubMed ID: 22591684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of anti-cancer drugs mediated by apoptosis and autophagy].
    Shimizu S
    Nihon Rinsho; 2015 Aug; 73(8):1302-7. PubMed ID: 26281682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Bcl-2 family of proteins as drug targets].
    Mazars A; Geneste O; Hickman J
    J Soc Biol; 2005; 199(3):253-65. PubMed ID: 16471266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.
    Shahar N; Larisch S
    Drug Resist Updat; 2020 Sep; 52():100712. PubMed ID: 32599435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.
    Watkins CL; Sayers EJ; Allender C; Barrow D; Fegan C; Brennan P; Jones AT
    Mol Ther; 2011 Dec; 19(12):2124-32. PubMed ID: 21934653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting BCL-2 regulated apoptosis in cancer.
    Campbell KJ; Tait SWG
    Open Biol; 2018 May; 8(5):. PubMed ID: 29769323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
    Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
    BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.
    Czabotar PE; Lessene G; Strasser A; Adams JM
    Nat Rev Mol Cell Biol; 2014 Jan; 15(1):49-63. PubMed ID: 24355989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nuclear orphan receptors NR4A as therapeutic target in cancer therapy.
    Deutsch AJ; Angerer H; Fuchs TE; Neumeister P
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1001-14. PubMed ID: 22583411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting anti-apoptotic BCL-2 family proteins for cancer treatment.
    Zhang X; Liu X; Zhou D; Zheng G
    Future Med Chem; 2020 Apr; 12(7):563-565. PubMed ID: 32083493
    [No Abstract]   [Full Text] [Related]  

  • 12. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer.
    Kolluri SK; Zhu X; Zhou X; Lin B; Chen Y; Sun K; Tian X; Town J; Cao X; Lin F; Zhai D; Kitada S; Luciano F; O'Donnell E; Cao Y; He F; Lin J; Reed JC; Satterthwait AC; Zhang XK
    Cancer Cell; 2008 Oct; 14(4):285-98. PubMed ID: 18835031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer.
    Weyhenmeyer B; Murphy AC; Prehn JH; Murphy BM
    Exp Oncol; 2012 Oct; 34(3):192-9. PubMed ID: 23070004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoting apoptosis as a strategy for cancer drug discovery.
    Fesik SW
    Nat Rev Cancer; 2005 Nov; 5(11):876-85. PubMed ID: 16239906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Bcl-2 for cancer therapy.
    Zhang L; Lu Z; Zhao X
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188569. PubMed ID: 34015412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2.
    Wang W; Gu F; Wei C; Tang Y; Zheng X; Ren M; Qin Y
    PLoS One; 2013; 8(4):e60701. PubMed ID: 23593287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NR4A1 (TR3) in cancer cells and tumors.
    Lee SO; Li X; Khan S; Safe S
    Expert Opin Ther Targets; 2011 Feb; 15(2):195-206. PubMed ID: 21204731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
    Adams JM; Cory S
    Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
    Morales AA; Kurtoglu M; Matulis SM; Liu J; Siefker D; Gutman DM; Kaufman JL; Lee KP; Lonial S; Boise LH
    Blood; 2011 Aug; 118(5):1329-39. PubMed ID: 21659544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.
    Hata AN; Engelman JA; Faber AC
    Cancer Discov; 2015 May; 5(5):475-87. PubMed ID: 25895919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.